By Dean Seal
Inogen said regulators have cleared its SIMEOX 200 Airway Clearance Device to be used by U.S. patients with chronic respiratory diseases.
The medical technology company said Monday that the Food and Drug Administration's 510(k) clearance paves the way for a limited launch of SIMEOX 200 in targeted sites next year.
The device promotes bronchial drainage and is intended for patients with chronic lung diseases associated with mucus hypersecretion and mucus retention, including chronic obstructive pulmonary diseases, or COPD, and cystic fibrosis.
Chief Executive Kevin Smith said the company intends to bring the device to patients within the next year.
Shares rose 3.6% to $8.89 in premarket trading.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 30, 2024 08:49 ET (13:49 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.